Las Vegas, NV -- (SBWIRE) -- 12/17/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Cereplast Inc (OTCMKTS:CERP), Brigus Gold Corp (USA) (NYSEMKT:BRD), Plug Power Inc (NASDAQ:PLUG), ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC)
Cereplast Inc (OTCMKTS:CERP) managed to keep its fall at 1.69% on below -normal volume of 9.45M shares. The stock settled at $0.0058 after floating in a range of $0.01 to $0.01. Its latest price has reached market capitalization of $4.18 million. Its 52-week range has been $0.01to $0.07. Cereplast, Inc. develops and commercializes bio-based resins. It provides Cereplast Compostables resins, which are compostable, bio-based, and ecologically sound substitutes for petroleum-based plastics targeting compostable bags, single-use food service products, and packaging applications.
Has CERP Found The Bottom and Ready To Move Up? Find Out Here
Brigus Gold Corp (USA) (NYSEMKT:BRD) traded up on a volume of 8.99 million, higher than its standard daily volume. Shares have gained 32.65% to $0.796. Over the last twelve months, the stock has lost-16.21% and faced a worst price of $0.41. Brigus Gold Corp. engages in the extraction, processing, and refining of gold deposits; and acquisition, exploration, and development of mineral properties principally in North America.
For How Long BRD s Gloss will Attract Investors? Find out via this report
Plug Power Inc (NASDAQ:PLUG) settled -6.70% lower at $1.95 on below -normal volume of 8.68M shares during the last trading day. The stock has its 12-month high at $2.24 and 52-week low price was $0.12. It traded in a range of $1.90 to $2.06 during the last trading day. Plug Power Inc., an alternative energy technology provider, engages in the design, development, commercialization, and manufacture of fuel cell systems for the industrial off-road markets worldwide.
Will PLUG Get Buyers Even After The Recent Rally? Find Out Here
In the last trading session, ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) was down on high volume, trading at a volume of 7.22M versus its average daily volume of 2.44 million shares. At $0.902, the stock has attained market capitalization of 51.50 million. mmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, engages in developing and commercializing immune-based therapies for the treatment of brain, ovarian, and other solid tumors. Its lead pipeline product is ICT-107, a therapeutic dendritic cell (DC) vaccine, which is in Phase IIb clinical trial for the treatment of glioblastoma multiforme (GBM) that is a common and lethal type of brain cancer.
Why Should Investors Buy IMUC After the Recent Fall? Just Go Here and Find Out
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)